Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 March 2025 to Question 35647 on Coronavirus: Research, if he will make an assessment of the potential impact of the Prescription Medicines Code of Practice Authority case rulings with reference to (a) AUTH/3835/10/23 and (b) 0316/10/24 on the governance of the Government’s mRNA research and development partnership with Moderna.

In April 2025, the UK Health Security Agency (UKHSA) was made aware that Moderna was to be issued a public reprimand by the Prescription Medicines Code of Practice Authority (PMCPA) appeal board. Moderna would be subject to an audit following two recent cases where they had been ruled to have breached the Association of the British Pharmaceutical Industry Code.

The Government has conducted an initial assessment of the PMCPA’s ruling, and has determined that it will not impact the delivery of the Moderna-United Kingdom Strategic Partnership.

The UKHSA will work with Moderna to ensure any recommendations from the report are duly considered and implemented, and to obtain assurance that these will be upheld for the duration of the partnership.